Q-omics provides the consensus-scored SPATA20 profile across patient tissues and cancer cell-line models. SPATA20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SPATA20 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SPATA20 RNA expression shows 17,759 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where SPATA20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA20 survival associations across molecular data types. SPATA20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA20 RNA expression–survival associations across cancer types. High SPATA20 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in BRCA, BLCA and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SPATA20 RNA expression.
This table summarizes SPATA20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPATA20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA20 shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, HNSC, LUAD and CHOL. The KIRC box plot shows higher SPATA20 RNA expression in tumor versus normal tissue (log2 FC = +0.760, t-test p < 0.001).
This table shows molecular features associated with SPATA20 in patient tissues and cancer cell lines. In patient samples, SPATA20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
